Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

SensoLyte® Rh110 Factor Xa Assay Kit

FRET Fluorometric
N° du produit ABIN1882458

Aperçu rapide pour SensoLyte® Rh110 Factor Xa Assay Kit (ABIN1882458)

Antigène

Voir toutes Factor Xa (FXa) Kits
Factor Xa (FXa) (Activated Coagulation Factor X (FXa))

Méthode de détection

Fluorometric

Application

Fluorescence Resonance Energy Transfer Microscopy (FRET)
  • Marque

    SensoLyte®

    Attributs du produit

    The SensoLyte® Rh110 Factor Xa Assay Kit provides a convenient assay for screening of FXa inhibitors or continuous assay of enzyme activity using a fluorogenic substrate. Upon FXa protease cleavage, this substrate generates the Rh110 (rhodamine 110) fluorophore which has a bright green fluorescence that can be detected at excitation/emission=490 nm/520 nm. The longer-wavelength spectra and higher extinction coefficient of the Rh110 provide greater sensitivity and less interference from other reaction components.
  • Commentaires

    FRET-based Assay Kit

    Restrictions

    For Research Use only
  • Conseil sur la manipulation

    Protect Components A and B from light and moisture.

    Stock

    -80 °C

    Stockage commentaire

    Store all kit components at -20 °C, except for Component C. Store Component C at -80 °C. Component D can be stored at room temperature for convenience
  • Antigène

    Factor Xa (FXa) (Activated Coagulation Factor X (FXa))

    Autre désignation

    Factor Xa

    Sujet

    Factor Xa (FXa) is a serine endopeptidase composed of two disulfide-linked subunits. FXa leads to blood clot formation by converting prothrombin to thrombin through the prothrombinase complex. FXa is generated from zymogen Factor X via the intrinsic and extrinsic pathways and is the rate-limiting step in the propagation of thrombin generation. In the presence of Ca2+ ions, FXa forms prothrombinase with factor Va on the phospholipid membrane of the activated platelets. FXa has emerged as an attractive target for drug discovery for thromboembolic diseases.
Vous êtes ici:
Chat with us!